ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells

Gefitinib, an EGFR tyrosine kinase inhibitor, is used to treat non-small cell lung cancer (NSCLC) patients with activating EGFR mutations. However, the resistance to gefitinib eventually emerges in most of the patients. To understand its mechanism, we generated two acquired gefitinib-resistant NSCLC...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncotarget
Prif Awduron: Qi, Mengfan, Tian, Ye, Li, Wang, Li, Dan, Zhao, Tian, Yang, Yuxin, Li, Qiwen, Chen, Sujun, Yang, Yan, Zhang, Zhixiong, Tang, Liang, Liu, Zhonghua, Su, Bo, Li, Fei, Feng, Yonghong, Fei, Ke, Zhang, Peng, Zhang, Fan, Zhang, Lei
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals LLC 2018
Pynciau:
Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5844726/
https://ncbi.nlm.nih.gov/pubmed/29552290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24147
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg